Januvia is the brand name for sitagliptin phosphate, a DPP-4 inhibitor used in type 2 diabetes. It is used as an adjunct to diet and exercise to improve glycemic control. The FDA first approved Januvia in October 2006.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00947011 |
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1) |
TERMINATED | PHASE2 |
| NCT00411411 |
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes |
COMPLETED | PHASE3 |
